These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Fattinger KE; Verotta D; Porchet HC; Munafo A; Le Cotonnec JY; Sheiner LB Am J Physiol; 1996 Oct; 271(4 Pt 1):E775-87. PubMed ID: 8897868 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME. Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN J Pharmacokinet Pharmacodyn; 2004 Dec; 31(6):441-61. PubMed ID: 16222784 [TBL] [Abstract][Full Text] [Related]
11. The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs. Agersø H; Koechling W; Knutsson M; Hjortkjaer R; Karlsson MO Eur J Pharm Sci; 2003 Nov; 20(3):335-40. PubMed ID: 14592699 [TBL] [Abstract][Full Text] [Related]
12. Pituitary and gonadal endocrine effects and pharmacokinetics of the novel luteinizing hormone-releasing hormone antagonist teverelix in healthy men--a first-dose-in-humans study. Erb K; Pechstein B; Schueler A; Engel J; Hermann R Clin Pharmacol Ther; 2000 Jun; 67(6):660-9. PubMed ID: 10872648 [TBL] [Abstract][Full Text] [Related]
13. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. Wong SL; Lau DT; Baughman SA; Fotheringham N; Menchaca D; Garnick MB J Clin Pharmacol; 2004 May; 44(5):495-502. PubMed ID: 15102870 [TBL] [Abstract][Full Text] [Related]
15. Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men. Finkelstein JS; Whitcomb RW; O'Dea LS; Longcope C; Schoenfeld DA; Crowley WF J Clin Endocrinol Metab; 1991 Sep; 73(3):609-20. PubMed ID: 1908484 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women. Nagaraja NV; Pechstein B; Erb K; Klipping C; Hermann R; Niebch G; Derendorf H Clin Pharmacol Ther; 2000 Dec; 68(6):617-25. PubMed ID: 11180022 [TBL] [Abstract][Full Text] [Related]
17. Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. Samant MP; Gulyas J; Hong DJ; Croston G; Rivier C; Rivier J J Med Chem; 2005 Jul; 48(15):4851-60. PubMed ID: 16033265 [TBL] [Abstract][Full Text] [Related]
18. Pulsatile intravenous infusion of recombinant human luteinizing hormone under acute gonadotropin-releasing hormone receptor blockade reconstitutes testosterone secretion in young men. Veldhuis JD; Iranmanesh A J Clin Endocrinol Metab; 2004 Sep; 89(9):4474-9. PubMed ID: 15356050 [TBL] [Abstract][Full Text] [Related]
19. Regulation of pituitary gonadotropin-releasing hormone receptors by pulsatile gonadotropin-releasing hormone injections in male rats. Modulation by testosterone. Garcia A; Schiff M; Marshall JC J Clin Invest; 1984 Sep; 74(3):920-8. PubMed ID: 6088587 [TBL] [Abstract][Full Text] [Related]
20. Additive effect of simultaneous continuous administration of degarelix and TAK-448 on LH suppression in a castrated rat model. Stalewski J; Hargrove DM; Wolfe M; Kohout TA; Kamal A Eur J Pharmacol; 2018 Apr; 824():24-29. PubMed ID: 29378196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]